Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 2010, 329646

Evaluation of Hepcidin Isoforms in Hemodialysis Patients by a Proteomic Approach Based on SELDI-TOF MS

Affiliations

Evaluation of Hepcidin Isoforms in Hemodialysis Patients by a Proteomic Approach Based on SELDI-TOF MS

Natascia Campostrini et al. J Biomed Biotechnol.

Abstract

The hepatic iron regulator hormone hepcidin consists, in its mature form, of 25 amino acids, but two other isoforms, hepcidin-20 and hepcidin-22, have been reported, whose biological meaning remains poorly understood. We evaluated hepcidin isoforms in sera from 57 control and 54 chronic haemodialysis patients using a quantitative proteomic approach based on SELDI-TOF-MS. Patients had elevated serum levels of both hepcidin-25 and hepcidin-20 as compared to controls (geometric means: 7.52 versus 4.69 nM, and 4.06 versus 1.76 nM, resp., P < .05 for both). The clearance effects of a single dialysis session by different dialysis techniques and membranes were also investigated, showing an average reduction by 51.3% +/- 29.2% for hepcidin-25 and 34.2% +/- 28.4% for hepcidin-20 but only minor differences among the different dialysis modalities. Measurement of hepcidin isoforms through MS-based techniques can be a useful tool for better understanding of their biological role in hemodialysis patients and other clinical conditions.

Figures

Figure 1
Figure 1
SELDI-TOF MS profile of hepcidin-24-spiked serum samples of hemodialysis patient (a) and control (b). The hepcidin isoforms hepcidin-20, hepcidin-24 (synthetic analogue, panel (B)), and hepcidin-25 are indicated by arrows.
Figure 2
Figure 2
Hepcidin-20 in controls and HD patients. Data presented as geometric mean with 95% confidence interval.
Figure 3
Figure 3
Hepcidin-25 in controls and HD patients. Data presented as geometric mean with 95% confidence interval.
Figure 4
Figure 4
Reduction Ratio (%) of serum hepcidin-25 (a) and hepcidin-20 (b) by the different hemodialysis techniques. (*Statistically significant P < .05).

Similar articles

See all similar articles

Cited by 14 PubMed Central articles

See all "Cited by" articles

References

    1. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102(3):783–788. - PubMed
    1. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090–2093. - PubMed
    1. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. Journal of Biological Chemistry. 2001;276(11):7806–7810. - PubMed
    1. De Domenico I, Nemeth E, Nelson JM, et al. The hepcidin-binding site on ferroportin is evolutionarily conserved. Cell Metabolism. 2008;8(2):146–156. - PMC - PubMed
    1. Suzuki H, Toba K, Kato K, et al. Serum hepcidin-20 is elevated during the acute phase of myocardial infarction. Tohoku Journal of Experimental Medicine. 2009;218(2):93–98. - PubMed

Publication types

LinkOut - more resources

Feedback